Pharming bacteriophage capable of splitting multiple diarrheogenic Escherichia coli and application thereof

Through the muscle tail phage vB_EcoM_XAM237 isolated from pig farm sewage, the problem of difficult to effectively prevent and treat diarrhea E. coliosis in the prior art is solved, and the broad-spectrum bactericidal effect on a variety of pathogenic bacteria is achieved, with alternative antibiotics The potential of the disease reduces the risk of bacterial resistance.

CN118956780APending Publication Date: 2024-11-15HARBIN VETERINARY RESEARCH INSTITUTE CHINESE ACADEMY OF AGRICULTURAL SCIENCES (CHINA ANIMAL HEALTH & EPIDEMIOLOGY CENTER HARBIN BRANCH CENTER)
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411097169.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-09
Publication Date
2024-11-15

AI Technical Summary

Technical Problem

The prior art is difficult to effectively prevent and treat porcine E. coli disease caused by diarrhea E. coli, and the use of antibiotics leads to increased bacterial resistance, threatening public health safety.

Method used

A strong phage vB_EcoM_XAM237 was isolated from the pig farm sewage. This phage was able to cleave a variety of diarrhea E. coli and Salmonella typhimurium typhimurium. It has strong acid-base and temperature tolerance and was resistant to whole genome sequencing and biology Characteristic analysis, the evolution tree was constructed and determined to be the muscle tail phage vB_EcoM_XAM237, used to prepare drugs or bactericides for the treatment and prevention of diseases.

Benefits of technology

This phage showed good bactericidal effect in in vitro antibacterial experiments, has broad-spectrum activity on various serotypes of enterotoxin-producing E. coli and Salmonella typhimurium typhimurium, and has the potential to replace antibiotic treatment, providing new prevention and treatment ideas , reducing the risk of bacterial resistance.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004988306950000081
    Figure BDA0004988306950000081
  • Figure BDA0004988306950000091
    Figure BDA0004988306950000091
  • Figure HDA0004988306960000011
    Figure HDA0004988306960000011
Patent Text Reader

Abstract

The invention discloses a virulent bacteriophage capable of splitting multiple diarrheogenic Escherichia coli and application of the virulent bacteriophage. The virulent bacteriophage is named as a muscular tail bacteriophage vBEcoMXAM237, and is preserved in the China Center for Type Culture Collection (CCTCC), and the preservation number is CCTCC NO: M20241095. The research finds that the virulent bacteriophage vBEcoMXAM237 can be used for cracking enterotoxigenic escherichia coli and salmonella gallinarum of various serotypes; an in-vitro bacteriostasis experiment result shows that the virulent bacteriophage vBEcoMXAM237 can effectively split host bacteria under different MOIs, is high in acid-base tolerance and temperature tolerance and clear in bioinformatics characteristic, has important significance on bacteriophage preparation treatment research, and has the potential of replacing antibiotic treatment and the application prospect.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to a bacteriophage and its application, in particular to a virulent bacteriophage capable of lysing a variety of diarrhea-causing Escherichia coli and its application. The present invention belongs to the field of biotechnology. Background Art

[0002] Escherichia coli disease in pigs is a common infectious disease caused by diarrheagenic Escherichia coli (DEC), which can cause severe diarrhea and sepsis in piglets, with high morbidity and mortality. According to their virulence characteristics and the symptoms of the disease caused, porcine intestinal diarrheagenic Escherichia coli can be divided into many types, including enterotoxigenic Escherichia coli (ETEC), attaching-effacing Escherichia coli (AEEC), Shigatoxin-producing Escherichia coli (STEC), etc. Among them, ETEC can not only cause diarrhea in pigs, but also cause diarrhea or death in humans, rabbits, cattle, sheep, dogs and cats. There are many serotypes of Escherichia coli, and the cross-immunity between different serotypes is insufficient. At present, there is no broad-spectrum protective vaccine that can effectively prevent all pathogenic Escherichia coli, which makes prevention and control difficult and causes huge economic losses to the breeding industry.

[0003] Clinically, antibiotics are currently the most common treatment for E. coli disease in pigs. However, with the large-scale and irregular use of antibiotics, various pathogenic bacteria, including E. coli, have developed drug resistance, and the spectrum of drug-resistant bacteria is constantly expanding and spreading faster and faster, seriously threatening people's health and public health safety. Therefore, in the era of "antibiotic reduction" and "antibiotic replacement", a new type of biological agent that can replace antibiotics is urgently needed, and bacteriophages, as the specialized "natural enemy" of bacteria, have become a hot research object.

[0004] Bacteriophage is a general term for viruses that can infect microorganisms such as bacteria, fungi, actinomycetes or spirochetes. Bacteriophages are widely distributed in nature and are known as "the most abundant biological entity in the biosphere". Compared with traditional antibiotic treatment, phage treatment of bacterial diseases has many advantages: strong specificity, can target specific pathogenic bacteria without affecting the normal flora in the host; phages are "living drugs" and their number will increase when the targeted bacterial population spreads; phages are non-toxic, they only invade bacteria but not animal cells; phage-resistant bacteria are still sensitive to other phages with similar target ranges; finding new phages is a relatively fast process, which can usually be completed within a few days or weeks, and is easy to grow and purify. At present, phages have been widely used in the treatment of bacterial infections in humans, animals and plants, as well as the removal of pathogens in the environment, food and feed. As a new type of biological agent, phages have great potential for development and utilization.

[0005] The present invention uses porcine enterotoxigenic Escherichia coli as the host bacteria, isolates and identifies a virulent phage from the sewage of a sow farm in Zasai Te Banner, Xing'an League, Inner Mongolia Autonomous Region, and conducts biological characteristics and whole genome analysis on it, providing a new prevention and control method for porcine Escherichia coli infection. Summary of the invention

[0006] The purpose of the present invention is to provide a strong phage capable of lysing a variety of diarrhea-causing Escherichia coli and its application.

[0007] In order to achieve the above object, the present invention adopts the following technical means:

[0008] The inventor of the present invention isolated and identified a virulent phage from sewage of a sow farm in Zasaite Banner, Xing'an League, Inner Mongolia Autonomous Region, and named it myotail phage vB_EcoM_XAM237. The phage can form round, transparent, and clear-edged plaques with a diameter of 1 mm on a double-layer agar plate. Electron microscopic observation shows that the head of myotail phage vB_EcoM_XAM237 is icosahedral symmetrical, with a diameter of 70.62 nm and a tail length of 101.62 nm. According to morphological classification, the phage belongs to the order Caudovirales and the family Myotailphaga; at pH The activity of the muscle-tailed phage vB_EcoM_XAM237 was kept high under the conditions of 3-10 and 4-50℃, and the optimal infection multiplicity was 0.01. The results of the one-step growth curve showed that the incubation period of the muscle-tailed phage vB_EcoM_XAM237 was 20 minutes, the lysis period was 20-55 minutes, and it entered the stable period after 50 minutes, with an average lysis amount of 32 PFU / cell. It could lyse Salmonella typhi and enterotoxigenic Escherichia coli. The results of the in vitro antibacterial experiment showed that the muscle-tailed phage vB_EcoM_XAM237 could effectively lyse at different MOIs. The host bacteria were analyzed; whole genome sequencing revealed that the genome of the muscle-tailed phage vB_EcoM_XAM237 was 170541 bp in length, with a GC content of 35%, was double-stranded DNA, contained 272 open reading frames, did not contain known virulence factors and resistance-related genes, and did not encode integrase; the evolutionary tree constructed based on the whole genome showed that the muscle-tailed phage vB_EcoM_XAM237 was most closely related to the Escherichia coli phage HY01 of the Straboviridae family and the Tequatrovirus genus.

[0009] On the basis of the above research, the present invention proposes a virulent phage capable of lysing a variety of diarrhea-causing Escherichia coli, named as myotail phage vB_EcoM_XAM237, which is deposited in the China Center for Type Culture Collection with a deposit number of CCTCC NO: M20241095.

[0010] Among them, preferably, the virulent bacteriophage vB_EcoM_XAM237 is capable of lysing enterotoxigenic Escherichia coli (ETEC) and Salmonella Gallinarum.

[0011] Among them, preferably, the enterotoxigenic Escherichia coli includes K88 serotype enterotoxigenic Escherichia coli and K99 serotype enterotoxigenic Escherichia coli.

[0012] Furthermore, the present invention also proposes the use of the virulent bacteriophage capable of lysing a variety of diarrhea-causing Escherichia coli in the preparation of drugs or bactericides for treating and / or preventing diseases caused by Salmonella and / or enterotoxigenic Escherichia coli.

[0013] Furthermore, the present invention also provides a bactericidal composition for preventing and treating various diarrhea-causing Escherichia coli, comprising the potent bacteriophage capable of lysing various diarrhea-causing Escherichia coli.

[0014] Among them, preferably, the multiple diarrheagenic Escherichia coli include K88 serotype enterotoxigenic Escherichia coli and K99 serotype enterotoxigenic Escherichia coli.

[0015] Compared with the prior art, the present invention has the following beneficial effects:

[0016] The virulent bacteriophage vB_EcoM_XAM237 isolated from pig farm sewage samples in the present invention can lyse multiple serotypes of enterotoxigenic Escherichia coli and Salmonella typhi, has strong acid-base tolerance and temperature tolerance, clear bioinformatics characteristics, and good in vitro antibacterial effect. It is of great significance to the research on bacteriophage preparation treatment, and has the potential and application prospects to replace antibiotic treatment. BRIEF DESCRIPTION OF THE DRAWINGS

[0017] Figure 1 This is a diagram of the purification results of the muscle tail phage vB_EcoM_XAM237;

[0018] Figure 2 This is the transmission electron microscopic morphology observation of the myotail phage vB_EcoM_XAM237;

[0019] Figure 3 This is a diagram of the biological identification results of the muscle tail phage vB_EcoM_XAM237;

[0020] Among them, A: Statistical bar graph of the tolerance of muscle-tail phage vB_EcoM_XAM237 to pH; B: Result graph of the tolerance of muscle-tail phage vB_EcoM_XAM237 to temperature; C: Statistical bar graph of the best MOI of muscle-tail phage vB_EcoM_XAM237; D: Line graph of the adsorption rate of muscle-tail phage vB_EcoM_XAM2373;

[0021] Figure 4 is a one-step growth curve of the myotail phage vB_EcoM_XAM237;

[0022] Figure 5 is the genome circle map of myotail phage vB_EcoM_XAM237;

[0023] Figure 6 This is the evolutionary tree of myotail phage vB_EcoM_XAM237;

[0024] Figure 7This is the in vitro lysis growth kinetics curve of the muscle-tailed phage vB_EcoM_XAM237.

[0025] Strain deposit information:

[0026] Nomenclature: Myoviridae vB_EcoM_XAM237

[0027] Classification name: Myoviridae vB_EcoM_XAM237

[0028] Collection Unit: China Center for Type Culture Collection

[0029] Deposit address: Wuhan University, Wuhan, China

[0030] Deposit number: CCTCC NO: M20241095

[0031] Preservation time: May 30, 2024. DETAILED DESCRIPTION

[0032] The present invention will be further described below in conjunction with specific embodiments, and the advantages and features of the present invention will become clearer as the description proceeds. However, it should be understood that the embodiments are exemplary only and do not constitute any limitation to the scope of the present invention. It should be understood by those skilled in the art that the details and forms of the technical solution of the present invention may be modified or replaced without departing from the spirit and scope of the present invention, but these modifications or replacements all fall within the protection scope of the present invention.

[0033] Example 1 Isolation and identification of myotail phage vB_EcoM_XAM237 and study of its biological characteristics

[0034] 1 Materials and methods

[0035] 1.1 Strains and samples

[0036] The strains used for phage host spectrum analysis included 1 strain of Salmonella Gallinarum purchased from China Industrial Microbiological Culture Collection Center, 1 strain of Salmonella Typhimurium purchased from China National Veterinary Microbiological Culture Collection Center, 1 strain of Salmonella Choleraesuis purchased from China Industrial Microbiological Culture Collection Center, 1 strain of Salmonella Enteritidis purchased from China Medical Bacteria Collection Center, 1 strain of Salmonella Pullorum purchased from China National Veterinary Microbiological Culture Collection Center, and 2 strains of enterotoxigenic Escherichia coli C83912 (K99) and C83903 (K88) ( coli) was purchased from the National Veterinary Microbial Collection Center. The sewage sample for isolating bacteriophages was collected from a sow farm in Zasaite Banner, Xing'an League, Inner Mongolia Autonomous Region in July 2022.

[0037] 1.2 Main Reagents

[0038] LB liquid culture medium was purchased from Haibo Biotechnology (Qingdao) Co., Ltd.; deoxyribonuclease (DNaseI) was purchased from Baoriyi Biotechnology (Beijing) Co., Ltd.; viral genome DNA / RNA extraction kit (spin column type) and ribonuclease (RNaseA) were purchased from Tiangen Biochemical Technology (Beijing) Co., Ltd.

[0039] 1.3 Main instruments and equipment

[0040] The desktop centrifuge (model X-15R Centrifuge) was purchased from Beckman Coulter, USA; the desktop digital shaker (model IS-RDS3C) was purchased from SCILOGEX, USA; the agarose horizontal electrophoresis apparatus (model DYCP-31DY) was purchased from Beijing Liuyi Biotechnology Co., Ltd.; and the incubator was purchased from Shanghai Jinghong Experimental Equipment Co., Ltd.

[0041] 1.4 Isolation, identification, purification and storage of bacteriophage

[0042] 1.4.1 Enrichment of phage

[0043] The collected sewage was transferred to a 50mL centrifuge tube, and after aseptic treatment, it was transferred to a 50mL sterile centrifuge tube to obtain a sterile sewage treatment solution. The sterile sewage treatment solution and LB liquid culture medium were mixed in a ratio of 1:1, and then 1 / 10 of enterotoxigenic Escherichia coli was added. After mixing, enrichment culture was carried out at room temperature overnight for 8 hours. The culture solution was collected in a 1.5mL sterile EP tube and aseptically treated to obtain the sample to be tested.

[0044] 1.4.2 Identification and purification of bacteriophage

[0045] Use the plaque test to preliminarily determine whether the sample contains specific phages for enterotoxigenic Escherichia coli. Spread 100 μL of bacterial solution evenly on the LB solid culture medium, take 10 μL of the sample to be tested and gently drop it on the culture medium. After it is completely absorbed, invert the plate and culture it in a 37°C incubator for 12 hours to observe whether plaques appear. For the sample to be tested that has plaques, use the double-layer plate method to further confirm whether there are plaques. If there are plaques, pick a single plaque and use the double-layer plate method to further purify and culture the phage until the plaques are basically the same in shape and size, and the purified phage can be obtained.

[0046] 1.4.3 Preservation of bacteriophages

[0047] The purified phage culture fluid was added to the host bacteria fluid in the logarithmic phase at a ratio of 1:100, and cultured at 37°C and 180 r / min for 6-8 h. The culture was centrifuged at 4°C and 12000 r / min for 10 min. The supernatant was collected by filtering through a 0.22 μm filter membrane, mixed with an equal volume of 50% glycerol, and stored at 4°C for later use.

[0048] 1.5 Phage morphology observation

[0049] 1.5.1 Phage Concentration

[0050] Take 100mL of phage culture medium, add DNaseI and RNaseA (final mass concentration is 1μg / mL), digest in a water bath at 37℃ for 3h, then add NaCl (final concentration is 1mol / L), place on ice for 2h after dissolution, centrifuge at 17000r / min for 15min, take the supernatant, add 10% (w / v) PEG8000, place in a refrigerator at 4℃ for 12h after dissolution. After the obtained solution is centrifuged at 16000r / min for 20min, collect the precipitate, resuspend and dissolve with 10mL PBS buffer to obtain phage concentrate. Extract the phage concentrate with chloroform 2-3 times to remove PEG8000. Add 1 / 10 chloroform to the concentrate, let it stand at room temperature for 1h, centrifuge at 4000r / min for 20min, repeat 2-3 times until the upper aqueous phase is clear, collect the aqueous phase to obtain the concentrated phage, use the double-layer plate method to determine the titer of the concentrated phage, and store it in a refrigerator at 4℃ for later use.

[0051] 1.5.2 Phage morphological observation

[0052] 20 μL of concentrated phage solution was dripped on the copper mesh and naturally precipitated at room temperature for 15 minutes. When the sample was not completely dry, 2% phosphotungstic acid (pH = 7.0) was dripped for 2 minutes, and the excess dye was absorbed. After standing at room temperature for 2 minutes, the phage morphology was observed using a Hitachi H-7650 transmission electron microscope. The phage was named myotail phage vB_EcoM_XAM237 and deposited in the China Center for Type Culture Collection with a deposit number of CCTCC NO: M20241095.

[0053] 1.6 Study on the biological characteristics of the muscle-tailed phage vB_EcoM_XAM237

[0054] 1.6.1 Determination of the lysis spectrum of the myotail phage vB_EcoM_XAM237

[0055] In order to determine the host range of the myotail phage vB_EcoM_XAM237, the strains used for lysis spectrum determination in Table 1 were cultured to the logarithmic phase, 100 μL of the test bacterial solution was evenly spread on the LB solid medium, and 10 μL of the phage solution was respectively dropped on the solid medium. After natural drying, it was cultured at 37°C for 6-8 hours. Observe whether transparent plaques appear. The experiment was repeated 3 times.

[0056] 1.6.2 pH and thermal stability analysis

[0057] In order to evaluate the stability of the myotail phage vB_EcoM_XAM237 at different pH values, the pH value of the LB liquid medium was adjusted using NaOH and HCl solutions. The pH gradient was set to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, and 12. 100 μL of phage solution was mixed evenly with 900 μL of LB medium with different pH values, incubated at 37°C for 2 h, and the titer of phage at different pH values ​​was determined by the double-layer plate method. In order to evaluate the stability of the myotail phage vB_EcoM_XAM237 at different temperatures, the temperature gradient was set to 4, 30, 37, 40, 50, and 60°C. 200 μL of phage solution was placed in a 1.5 mL EP tube, and the EP tube was incubated at different temperatures for 2 h. The titer of phage at different temperatures was determined by the double-layer plate method. The experiment was repeated 3 times and the average value was taken.

[0058] 1.6.3 Determination of the optimal multiplicity of infection

[0059] The host bacteria were cultured to the logarithmic growth phase (1×10 8 CFU / mL), add muscle tail phage vB_EcoM_XAM237 solution and bacterial solution into centrifuge tubes according to MOI of 0.001, 0.01, 0.1, 1, 10, 100, shake and mix, and culture in a 37°C incubator for 8 hours. Centrifuge at 12000r / min for 10 minutes, take the supernatant, and determine the phage titer by double-layer plate method. The MOI corresponding to the highest muscle tail phage vB_EcoM_XAM237 titer is the optimal MOI. The experiment was repeated 3 times, and the host bacterial culture solution without phage was set as the experimental control.

[0060] 1.6.4 Myotail phage vB_EcoM_XAM237 adsorption experiment

[0061] Take the host bacteria in the logarithmic growth phase (1×10 8 CFU / mL) was added to a centrifuge tube, and the muscle tail phage vB_EcoM_XAM237 solution was added at the optimal MOI. After mixing, it was immediately placed in an incubator at 37°C for incubation. Samples were taken every 2.5 minutes during 0-5 minutes, and every 5 minutes during 5-30 minutes. The phage titer of the sample was determined by the double-layer plate method, and the non-adsorption rate of phage (%) = (X0 / X1) × 100% (X0 = free phage titer; X1 = initial phage titer). The adsorption curve of muscle tail phage vB_EcoM_XAM237 was drawn using GraphPadPrism 9.0 software, with time as the horizontal axis and the non-adsorption rate of phage as the vertical axis.

[0062] 1.6.5 One-step growth curve

[0063] Take 4 mL of host bacteria (1×108 CFU / mL) was added to a centrifuge tube, and the muscle tail phage vB_EcoM_XAM237 solution was added at the optimal MOI. After mixing, it was placed in a 37°C incubator for 20 minutes, centrifuged at 8000r / min for 5 minutes, the supernatant was aspirated, and the precipitate was rinsed with PBS buffer. The centrifugation operation was repeated twice to wash away the unbound free phages. The precipitate was resuspended with PBS buffer and placed in a 37°C incubator for static culture. Samples were taken every 5 minutes for 60 minutes. The phage titer of the sample was determined by the double-layer plate method, and the incubation period, outbreak period and lysis amount of the phage were calculated. The experiment was repeated 3 times. With time as the horizontal axis and the logarithm of the phage titer as the vertical axis, GraphPadPrism 9.0 software was used to draw a one-step growth curve data graph.

[0064] 1.7 Extraction and bioinformatics analysis of the myotail phage vB_EcoM_XAM237 genome

[0065] The myotail phage vB_EcoM_XAM237 genome was extracted according to the operating instructions of the viral genome DNA / RNA extraction kit (centrifugal column type), and the integrity of the genome was detected by 1% agarose gel electrophoresis. The qualified genome samples were sent to Tianjin Novogene Sequencing Company for second-generation sequencing.

[0066] GeneMarks was used to predict the open reading frame of the genome; RAST (http: / / rast.nmpdr.org / ) was used to annotate the whole phage genome, and the online BLAST tool (http: / / www.ncbi.nlm.nih.gov / BLAST) was used for comparison analysis to predict the genome function; tRNA was predicted by tRNAscan-SE software (Version 1.3.1); the CGE platform (https: / / www.genomicepidemiology.org / ) and the virulence factor library (http: / / www.mgc.ac.cn / cgi-bin / VFs / v5 / main.cgi) were used to screen the putative antibiotic resistance genes and virulence factors; the online drawing tool CGView (http: / / cgview.ca) was used to draw the phage genome circle map; based on the NCBI database, the whole genome sequences of the phage isolated in this experiment and other phages were compared; Mega11.0 software was used to construct a phylogenetic tree for the genomes of 20 phages with close similarity and the phage isolated in the present invention to analyze the affinity.

[0067] 1.8 Phage lysis assay in vitro

[0068] The host bacteria were cultured to the logarithmic growth phase (1×108 CFU / mL), take 2 mL in a sterile test tube, add muscle tail phage vB_EcoM_XAM237 solution and 10mmol / L CaCl in the centrifuge tube according to MOI of 0.1, 1, and 10, respectively. 2 , placed in a shaker at 37°C, 180 r / min, and measured OD every 1 h 600 , and the test was continued for 12 hours. The test was repeated 3 times. 600 The vertical axis was used to draw the kinetic curve of phage lysis growth in vitro using GraphPad Prism9.0 software.

[0069] 2 Results

[0070] 2.1 Phage isolation, purification and identification results

[0071] Using enterotoxigenic Escherichia coli as the host bacteria, a virulent phage was successfully isolated from the sewage sample of a sow farm in Zasaite Banner, Xing'an League, Inner Mongolia Autonomous Region, and named as myoviridae vB_EcoM_XAM237. After the myoviridae vB_EcoM_XAM237 was purified by the double-layer plate method, the results were observed as follows Figure 1 As shown, the plaques are uniform in size, round, transparent, with clear edges and a diameter of 1 mm, indicating that the muscle tail phage vB_EcoM_XAM237 was successfully purified.

[0072] 2.2 Phage morphology observation

[0073] Transmission electron microscopy showed Figure 2 , it can be seen that the head of the myotail phage vB_EcoM_XAM237 virus particle is icosahedral symmetrical, with a diameter of 70.62nm and a tail length of 101.62nm. According to morphological classification, this phage belongs to the order Caudovirales and the family Myoviridae.

[0074] 2.3 Analysis of biological characteristics of bacteriophages

[0075] 2.3.1 Determination of host spectrum of phage

[0076] The sensitivity test of the purified muscle-tailed phage vB_EcoM_XAM237 was carried out by double-layer plate method. The results showed that the muscle-tailed phage vB_EcoM_XAM237 could lyse Salmonella enterica serotypes and enterotoxigenic Escherichia coli, and had lysing effects on enterotoxigenic Escherichia coli of serotypes K88 and K99.

[0077] Table 1 Host spectrum analysis of myotail phage vB_EcoM_XAM237

[0078]

[0079]

[0080] Note: a “+” indicates lysis (plaque formation), and “-” indicates no lysis (no plaque formation);

[0081] b "++" indicates clear plaques; "+" indicates unclear plaques

[0082] 2.3.2 pH and thermal stability analysis

[0083] Figure 3 A is a statistical bar graph of the pH tolerance of the muscle-tail phage vB_EcoM_XAM237. The results show that the survival rate of the muscle-tail phage vB_EcoM_XAM237 is 0 at pH 1 (extremely acidic) and pH 11-12 (extremely alkaline), indicating that the phage is in an inactivated state under these pH conditions; at pH 2, the survival rate drops to 35%, with more inactivation, but a portion still survives; at pH 3-4, the phage survival rate decreases slightly, but can still be maintained at a relatively high titer; at pH 5-10, the phage survival rate is basically maintained at 100%. These results show that the phage vB_EcoM_XAM237 can still maintain antibacterial activity in a wider pH range, indicating that it has a certain tolerance to acid and alkali. The temperature tolerance results of the muscle-tail phage vB_EcoM_XAM237 are shown in the figure. Figure 3 As shown in Figure B, the results show that the myotail phage vB_EcoM_XAM237 was incubated at 4, 30, 37, 40, 50, and 60°C, and it was found that the survival rate of the phage decreased slightly at 50°C; at 60°C, the phage survival rate was 0. This shows that the phage is not resistant to high temperatures and is stable at conventional ambient temperatures and the growth temperature suitable for most bacteria.

[0084] 2.3.3 Determination of the optimal multiplicity of infection

[0085] The best MOI statistical bar chart of muscle tail phage vB_EcoM_XAM237 is as follows Figure 3 As shown in C, the results show that when the infection multiplicity is 0.01, the titer of myotail phage vB_EcoM_XAM237 is the highest, reaching about 1×10 9 PFU / mL. Therefore, the optimal MOI of vB_EcoM_XAM237 is 0.01.

[0086] 2.3.4 Phage adsorption experiment

[0087] The adsorption rate of the muscle tail phage vB_EcoM_XAM237 was measured. The adsorption rate line graph of the muscle tail phage vB_EcoM_XAM2373 is shown in Figure 3 As shown in D, the results show that when vB_EcoM_XAM237 is adsorbed for 10 minutes, the non-adsorption rate is 30.29%; when it is adsorbed for 15 minutes, it is 13.76%; at 20, 25, and 30 minutes, the adsorption rate remains basically unchanged. This shows that the myotail phage vB_EcoM_XAM237 has a high affinity with the host bacteria, and the highest adsorption rate is 97.23%.

[0088] 2.3.5 One-step growth curve

[0089] Figure 4 This is a one-step growth curve of the muscle-tail phage vB_EcoM_XAM237. The results show that the incubation period of the muscle-tail phage vB_EcoM_XAM237 is 20 minutes, the lysis period is 20 to 50 minutes, and it enters the stable period after 50 minutes. The average lysis amount is 32 PFU / cell.

[0090] 2.4 Analysis of genome sequencing results

[0091] The annotated genome map is shown in Figure 5 The sequencing results showed that the genome of the myotail phage vB_EcoM_XAM237 was double-stranded DNA with a total length of 170541 bp and a GC content of 35%. GeneMarks predicted that the vB_EcoM_XAM237 genome had 272 open reading frames (ORFs). The whole genome of the phage was annotated by RAST and compared using the online BLAST tool.

[0092] The evolutionary tree based on the whole genome is shown in Figure 6 As shown, the results indicate that vB_EcoM_XAM237 is most closely related to Escherichia coli phage HY01 and belongs to the Straboviridae family and the Tequatrovirus genus.

[0093] 2.5 Phage In vitro Antibacterial Test

[0094] Figure 7 The figure is a graph of the in vitro lysis growth kinetics of the muscle-tailed phage vB_EcoM_XAM237. The results show that the muscle-tailed phage vB_EcoM_XAM237 can effectively lyse enterotoxigenic Escherichia coli at different MOIs. Figure 7 It can be seen that from 1 hour onwards, the number of enterotoxigenic Escherichia coli in the experimental group was always lower than that in the control group. When the MOI was 1 and 10, the host bacteria could maintain an OD of 600= about 0.1, indicating that bacteriophage vB_EcoM_XAM237 has a good bactericidal effect, and the bactericidal effect is proportional to MOI.

[0095] 3 Conclusion

[0096] The present invention successfully separated and identified a virulent bacteriophage vB_EcoM_XAM237 from the sewage of a sow farm. The phage has a short incubation period, a fast lysis speed, a short lysis cycle, and a strong lysis ability. The phage can lyse enterotoxigenic Escherichia coli and Salmonella typhi, and has a lysis effect on enterotoxigenic Escherichia coli of serotypes K88 and K99, making it a relatively broad-spectrum phage. In addition, the phage is acid- and alkali-resistant, can stably exist at conventional ambient temperatures and suitable growth temperatures for most bacteria, and meets clinical application requirements. It shows good bactericidal effects in in vitro antibacterial tests, and provides a new prevention and treatment idea and strategy for the breeding industry under the general background of reducing and prohibiting antibiotics.

Claims

1. A virulent bacteriophage capable of lysing a variety of diarrheagenic Escherichia coli (DEC), named as myotail phage vB_EcoM_XAM237, which is deposited in the China Center for Type Culture Collection with a deposit number of CCTCC NO: M20241095.

2. Use of the virulent bacteriophage capable of lysing a variety of diarrhea-causing Escherichia coli as claimed in claim 1 in the preparation of drugs or bactericides for treating and / or preventing diseases caused by Salmonella typhi and / or Escherichia coli, wherein the Escherichia coli include enterotoxigenic Escherichia coli of serotype K88 and enterotoxigenic Escherichia coli of serotype K99.

3. A bactericidal composition for preventing and treating various diarrhea-causing Escherichia coli, characterized in that: It comprises the virulent bacteriophage capable of lysing a variety of diarrhea-causing Escherichia coli as described in claim 1.

4. The bactericidal composition according to claim 3, characterized in that The multiple diarrheagenic Escherichia coli include K88 serotype enterotoxigenic Escherichia coli and K99 serotype enterotoxigenic Escherichia coli.